지아이이노베이션

358570KOSDAQ

56.0 / 100

Reference Date: 2026-09-08

Financial Score17.5 / 40

News Sentiment20.4 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 2.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

GI Innovation is a biotechnology company specializing in the development of next-generation immune therapies based on fusion proteins, with key drug pipelines including GI-101, GI-102, GI-301, and GI-108. The company utilizes its proprietary GI-SMART™ platform technology to rapidly develop novel bispecific fusion proteins and has achieved growth through technology transfer collaborations with global partners.

Number of Employees

82people

Average Salary

131.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

4.86Industry Average 1.200.0Point

4.1x industry avg (risky)

ROE

-48.28Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

1.47Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲11921.9% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲12.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -77.1% (improving, 3yr)

Detailed News Sentiment

11 totalPositive 10Neutral 1Negative 0Average Sentiment Score 81.8

Positive
"美 신속진출"…패스트트랙 공략하는 K-바이오
미국 FDA의 패스트트랙 지정으로 지아이이노베이션의 신약 개발 및 승인 과정이 가속화될 가능성이 높아져 긍정적 영향 기대.
Neutral
에이비온 5.6개월·에이비엘은 현금 순유입…기술이전이 가른 ‘자금...
Positive
지아이이노베이션, 요로상피암 신약 FDA 패스트트랙 지정에 5% 상승 ...
지아이이노베이션의 신약 'GI-101A'가 FDA 패스트트랙 지정으로 인해 주가가 5% 상승했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 8,770Won52-week high 20,90052-week low 6,820

1-month return4.0Point

1m +2.57% (slight rise)

Volume trend3.0Point

Volume flat

Detailed Disclosure

10 totalPositive 0Neutral 10Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-09-04
Neutral투자판단관련주요경영사항(임상시험계획변경승인신청) (GI102 제1/2상 임상시험계획 호주 인체연구윤리위원회 (HREC) 변경승인 신청)2026-08-21
Neutral주식등의대량보유상황보고서(약식)2026-08-20
Neutral반기보고서 (2026.06)2026-08-14
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-10